中文版吸入药物满意度量表的信效度检验及应用  

Reliability and validity test and application of the Chinese version of the Feeling of Satisfaction with Inhaler

作　　者：孟玮玮 赵志琪 熊若言 钟严俊 曾慧卉 陈燕[1] MENG Weiwei;ZHAO Zhiqi;XIONG Ruoyan;ZHONG Yanjun;ZENG Huihui;CHEN Yan(Department of Pulmonary and Critical Care Medicine,Second Xiangya Hospital,Central South University,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院呼吸与危重症医学科,长沙410011

出　　处：《中南大学学报（医学版）》2023年第12期1854-1864,共11页Journal of Central South University ：Medical Science

基　　金：国家自然科学基金(82070049)。

摘　　要：目的:吸入药物满意度是影响慢性气道疾病吸入依从性和吸入药物疗效的重要因素,采用科学有效的方法评估患者的吸入药物满意度,对改善临床结局具有重要意义。吸入药物满意度量表(Feeling of Satisfaction with Inhaler-10,FSI-10)专门用于评估慢性气道疾病患者的吸入药物满意度,但在国内尚未见该量表的应用。本研究旨在检验中文版FSI-10在中国慢性气道疾病人群中的信度及效度,并探究中国慢性气道疾病患者吸入药物满意度现状及吸入药物满意度的影响因素。方法:对英文版FSI-10量表进行翻译、回译和文化调试,确定中文版量表条目。纳入2022年6月至10月于中南大学湘雅二医院就诊的322例慢性阻塞性肺疾病(以下简称“慢阻肺”)和支气管哮喘(以下简称“哮喘”)患者,收集患者的相关临床数据,并采用中文版FSI-10对患者进行问卷调查。采用内容效度指数(content validity index,CVI)及探索性因子分析分别检验中文版FSI-10的内容与结构效度;克龙巴赫α系数、分半信度和重测信度检验量表的信度。采用logistic回归分析探究吸入药物满意度的影响因素。结果:信效度分析结果表明:中文版FSI-10的CVI为0.983,探索性因子分析提取出1个公因子,累计解释总变异量表的73.114%。中文版FSI-10的克龙巴赫α系数为0.913,Guttman折半系数为0.905,重测信度为0.727(P<0.001)。慢性气道疾病患者中文版FSI-10的得分为38.92±4.26,慢阻肺患者的高满意度(FSI-10得分≥40)占比显著低于哮喘患者(71.3%vs 87.9%,P<0.01)。回归分析结果显示高龄(年龄≥70岁)是吸入药物低满意度的独立危险因素,哮喘诊断可降低患者吸入药物低满意度的风险。结论:中文版FSI-10在慢阻肺和哮喘人群中具有良好的信度和效度,可在中国慢性气道疾病人群中进一步推广及应用。临床医师应定期对慢性气道疾病患者,尤其是高龄、症状严重、病程�Objective:Inhaler satisfaction is an important factor affecting inhaler adherence and the efficacy of inhalers in chronic airway diseases.Using a scientific and effective method to assess patients’satisfaction with inhalers is of great significance for improving clinical outcomes.The Feeling of Satisfaction with Inhaler-10(FSI-10)is specifically designed to assess patients’inhaler satisfaction in chronic airway diseases,but the application research on this scale is not available in China.This study aims to evaluate the reliability and validity of the Chinese version of FSI-10,describe the current status of inhaler satisfaction and discuss the associated variables in Chinese patients with chronic airway disease.Methods:Based on the English version of FSI-10,items of the Chinese version of FSI-10 were determined after forward-backward translation and cultural adaption.Totally,322 patients with chronic obstructive pulmonary disease(COPD)and asthma were enrolled from the Second Xiangya Hospital of Central South University from June to October 2022.We collected associated clinical variables and inhaler satisfaction using the Chinese version of FSI-10.The content validity of the scale was expressed by content validity index(CVI)and the construct validity was analyzed by exploratory factor analysis(EFA).The reliability of the scale was expressed by Cronbach’sαcoefficient,the split-half reliability and test-retest reliability.A multivariate logistic regression was conducted to examine variables related to inhaler satisfaction.Results:The reliability and validity analysis showed that the CVI was 0.983.One factor was extracted from the Chinese version of FSI-10 and the cumulative variance contribution rate was 73.114%.The Cronbach’sαof the scale was 0.913,the Guttman’s half-reliability coefficient was 0.905,and the test-retest reliability was 0.727(P<0.001).In addition,the total score of the scale for patients was 38.92±4.26 points and the proportion of high satisfaction(the score of FSI-10≥40)in patients wi

关 键 词：肺疾病 阻塞性 药物满意度 信度 效度 

分 类 号：R969[医药卫生—药理学]